Abstract:
BACKGROUND:Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥65 years) patients in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC. METHODS:We compared clinical outcomes for patients with AML-MRC treated with azacitidine or conventional care regimens (CCR; induction chemotherapy, low-dose cytarabine, or supportive care only) overall and within patient subgroups defined by cytogenetic risk (intermediate or poor) and age (65-74 years or ≥75 years). The same analyses were used to compare azacitidine with low-dose cytarabine in patients who had been preselected to low-dose cytarabine before they were randomized to receive azacitidine or CCR (ie, low-dose cytarabine). RESULTS:Median overall survival was significantly prolonged with azacitidine (n = 129) versus CCR (n = 133): 8.9 versus 4.9 months (hazard ratio 0.74, [95%CI 0.57, 0.97]). Among patients with intermediate-risk cytogenetics, median overall survival with azacitidine was 16.4 months, and with CCR was 8.9 months (hazard ratio 0.73 [95%CI 0.48, 1.10]). Median overall survival was significantly improved for patients ages 65-74 years treated with azacitidine compared with those who received CCR (14.2 versus 7.3 months, respectively; hazard ratio 0.64 [95%CI 0.42, 0.97]). Within the subgroup of patients preselected to low-dose cytarabine before randomization, median overall survival with azacitidine was 9.5 months versus 4.6 months with low-dose cytarabine (hazard ratio 0.77 [95%CI 0.55, 1.09]). Within the low-dose cytarabine preselection group, patients with intermediate-risk cytogenetics who received azacitidine had a median overall survival of 14.1 months versus 6.4 months with low-dose cytarabine, and patients aged 65-74 years had median survival of 14.9 months versus 5.2 months, respectively. Overall response rates were similar with azacitidine and CCR (24.8% and 17.3%, respectively), but higher with azacitidine versus low-dose cytarabine (27.2% and 13.9%). Adverse events were generally comparable between the treatment arms. CONCLUSIONS:Azacitidine may be the preferred treatment for patients with AML-MRC who are not candidates for intensive chemotherapy, particularly patients ages 65-74 years and those with intermediate-risk cytogenetics. TRIAL REGISTRATION:This study was registered at clinicalTrials.gov on February 16, 2010 ( NCT01074047 ).
journal_name
BMC Cancerjournal_title
BMC cancerauthors
Seymour JF,Döhner H,Butrym A,Wierzbowska A,Selleslag D,Jang JH,Kumar R,Cavenagh J,Schuh AC,Candoni A,Récher C,Sandhu I,Del Castillo TB,Al-Ali HK,Falantes J,Stone RM,Minden MD,Weaver J,Songer S,Beach CL,Dombret Hdoi
10.1186/s12885-017-3803-6subject
Has Abstractpub_date
2017-12-14 00:00:00pages
852issue
1issn
1471-2407pii
10.1186/s12885-017-3803-6journal_volume
17pub_type
杂志文章,多中心研究,随机对照试验相关文献
BMC CANCER文献大全abstract:BACKGROUND:Cervical cancer is the most common malignant gynecological cancer, and lymphatic metastasis can occur in the early stage of tumor growth. Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), a marker for lymphatic endothelium, provides powerful tools for studying tumor lymphangiogenesis. The purpose ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-64
更新日期:2009-02-21 00:00:00
abstract:BACKGROUND:Despite the excellent results obtained with hormone therapy, the long treatment period and the side effects associated with its use make patient adherence difficult. Moreover, certain aspects of health care can mitigate or exacerbate non-adherence. This study aimed to identify the factors associated with adh...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-397
更新日期:2014-06-03 00:00:00
abstract:BACKGROUND:B7-H4, a co-inhibitory molecule of the B7 family, can restrain T cell proliferation, cytokine secretion and the development of cytotoxicity. B7-H4 is expressed in tumor tissues at a higher level than in normal tissues, and has a potential effect to protect tumors from anti-tumor immune responses. This case-c...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-394
更新日期:2009-11-11 00:00:00
abstract:BACKGROUND:Exercise has favorable effects on biomarkers associated with a lower risk of breast cancer, however it is unclear if higher doses of exercise provide additional effects. No clinical trial has systematically examined how different exercise volumes influence the mechanisms underlying breast cancer etiology. Th...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1186/1471-2407-14-919
更新日期:2014-12-06 00:00:00
abstract:BACKGROUND:There is an unmet clinical need for better prognostic and diagnostic tools for renal cell carcinoma (RCC). METHODS:Human Protein Atlas data resources, including the transcriptomes and proteomes of normal and malignant human tissues, were searched for RCC-specific proteins and cubilin (CUBN) identified as a ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-3030-6
更新日期:2017-01-04 00:00:00
abstract:BACKGROUND:Internal mammary and/or supraclavicular (IM-SC) lymph node (LN) recurrence without distant metastasis (DM) in patients with breast cancer is rare, and there have been few reports on its clinical outcomes. METHODS:We enrolled 4237 patients with clinical stage I-IIIC breast cancer treated between January 2007...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07442-8
更新日期:2020-09-29 00:00:00
abstract:BACKGROUND:The development and evaluation of new therapeutic approaches for malignant mesothelioma has been sparse due, in part, to lack of suitable tumor models. METHODS:We established primary mesothelioma cultures from pleural and ascitic fluids of five patients with advanced mesothelioma. Electron microscopy and im...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-1362-2
更新日期:2015-05-08 00:00:00
abstract:BACKGROUND:To evaluate radiomics analysis in neuro-oncologic studies according to a radiomics quality score (RQS) system to find room for improvement in clinical use. METHODS:Pubmed and Embase were searched up the terms radiomics or radiogenomics and gliomas or glioblastomas until February 2019. From 189 articles, 51 ...
journal_title:BMC cancer
pub_type: 杂志文章,meta分析
doi:10.1186/s12885-019-6504-5
更新日期:2020-01-10 00:00:00
abstract:BACKGROUND:Solid tumours are less oxygenated than normal tissues. This is called tumour hypoxia and leads to resistance to radiotherapy and chemotherapy. The molecular mechanisms underlying such resistance have been investigated in a range of tumour types, including the adult brain tumours glioblastoma, yet little is k...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-5476-9
更新日期:2019-04-03 00:00:00
abstract:BACKGROUND:The preoperative characterization of thyroid nodules is a challenge for the clinicians. Fine-needle aspiration (FNA) is the commonly used pre-operative technique for diagnosis of malignant thyroid tumor. However, many benign lesions, with indeterminate diagnosis following FNA, are referred to surgery. There ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-492
更新日期:2014-07-08 00:00:00
abstract:BACKGROUND:The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this ef...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究
doi:10.1186/s12885-016-2692-4
更新日期:2016-08-20 00:00:00
abstract:BACKGROUND:Elucidating the molecular mechanisms by which tumors become resistant to Herceptin is critical for the treatment of Her2-overexpressed metastatic breast cancer. METHODS:To further understand Herceptin resistance mechanisms at the molecular level, we used comparative proteome approaches to analyze two human ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-8-286
更新日期:2008-10-04 00:00:00
abstract:BACKGROUND:Multidrug resistance (MDR) is a phenomenon that is often associated with decreased intracellular drug accumulation in patient's tumor cells resulting from enhanced drug efflux. It is related to the overexpression of a membrane protein, P-glycoprotein (Pgp-170), thereby reducing drug cytotoxicity. A variety o...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-4-13
更新日期:2004-04-17 00:00:00
abstract:BACKGROUND:Increasing the biological effective dose (BED) of radiotherapy for non-small cell lung cancer (NSCLC) can increase local control rates and improve overall survival. Compared with conventional fractionated radiotherapy, accelerated hypofractionated radiotherapy can yield higher BED, shorten the total treatmen...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2314-1
更新日期:2016-04-23 00:00:00
abstract:BACKGROUND:A universal hallmark of cancer cells is the change in their glycosylation phenotype. One of the most frequent alterations in the normal glycosylation pattern observed during carcinogenesis is the enhancement of α(1,6)linked fucose residues of glycoproteins, due to the up-regulation of the α(1,6)fucosyltransf...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-508
更新日期:2011-12-07 00:00:00
abstract:BACKGROUND:There is no consensus regarding resection of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour in later stages of the disease. We...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1186/1471-2407-14-741
更新日期:2014-10-02 00:00:00
abstract:BACKGROUND:Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy under a compassionate ...
journal_title:BMC cancer
pub_type: 临床试验,杂志文章
doi:10.1186/s12885-016-2201-9
更新日期:2016-02-24 00:00:00
abstract:BACKGROUND:Studies comparing the effect of antiangiogenic agents targeting different angiogenic pathways are sparse. The purpose of this study was to compare the effect of properdistatin and sunitinib treatment in a preclinical model of malignant melanoma. Properdistatin is a small peptide derived from the thrombospond...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3404-4
更新日期:2017-06-12 00:00:00
abstract:BACKGROUND:Oncogene amplification and overexpression occur in tumor cells. Amplification status may provide diagnostic and prognostic information and may lead to new treatment strategies. Chromosomal regions 8p12, 8q24, 11q13, 17q12 and 20q13 are recurrently amplified in breast cancers. METHODS:To assess the frequenci...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-6-245
更新日期:2006-10-13 00:00:00
abstract:BACKGROUND:Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America. METHODS:Eleven LS hereditary cancer registrie...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3599-4
更新日期:2017-09-05 00:00:00
abstract:BACKGROUND:The clinical implication of Ras/Raf/ERK pathway activity in breast cancer tissue and its association with response to chemotherapy is controversial. We aimed to explore the value of p90RSK phosphorylation, a downstram molecule of the pathway, in predicting chemotherapy response in breast cancer. METHODS:The...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-12-585
更新日期:2012-12-10 00:00:00
abstract:: ...
journal_title:BMC cancer
pub_type: 社论,历史文章
doi:10.1186/s12885-018-5020-3
更新日期:2018-11-12 00:00:00
abstract:BACKGROUND:The Michigan Prevention Research Center, the University of Michigan Schools of Nursing, Public Health, and Medicine, and the Michigan Department of Community Health propose a multidisciplinary academic-clinical practice three-year project to increase breast cancer screening among young breast cancer survivor...
journal_title:BMC cancer
pub_type: 杂志文章,随机对照试验
doi:10.1186/1471-2407-13-97
更新日期:2013-03-01 00:00:00
abstract:BACKGROUND:The neutrophil-to-lymphocyte ratio (NLR), a simple marker of the systemic inflammatory response in critical care patients, has been suggested as an independent prognostic factor for several solid malignancies. We investigated the utility of pretreatment NLR as a prognosticator in patients who presented with ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2134-3
更新日期:2016-02-16 00:00:00
abstract:BACKGROUND:Previous data from our laboratory has indicated that there is a functional link between the beta-adrenergic receptor signaling pathway and the G-protein inwardly rectifying potassium channel (GIRK1) in human breast cancer cell lines. We wanted to determine if GIRK channels were expressed in lung cancers and ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-5-104
更新日期:2005-08-18 00:00:00
abstract:BACKGROUND:Breast cancer incidence varies between social groups, but differences have not been thoroughly examined in New Zealand. The objectives of this study are to determine whether trends in breast cancer incidence varied by ethnicity and socioeconomic position between 1981 and 2004 in New Zealand, and to assess po...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-10-674
更新日期:2010-12-07 00:00:00
abstract:BACKGROUND:The survival following transarterial chemoembolization (TACE) alone is still low in unresectable hepatocellular carcinoma (HCC) with almost patients developing disease progression after treatment. There is need to investigate additional therapeutic options that would intensify the initial response to TACE. T...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2894-9
更新日期:2016-11-03 00:00:00
abstract::Following publication of the original article [1], the authors reported the following error is the article. ...
journal_title:BMC cancer
pub_type: 杂志文章,已发布勘误
doi:10.1186/s12885-019-6367-9
更新日期:2019-11-29 00:00:00
abstract:BACKGROUND:Lymphovascular invasion (LBVI) including lymphatic (LVI) and blood (BVI) vessel invasion is a critical step in cancer metastasis. In breast cancer, the optimal detection method of LBVI remains unclear. This research aimed to compare the prognostic value of different assessments of the LVI and BVI in patients...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-676
更新日期:2014-09-18 00:00:00
abstract:BACKGROUND:MicroRNAs in solid malignancies can behave as predictors of either good or poor outcome. This is the case with members of the miR-200 family, which are the primary regulators of the epithelial to mesenchymal transition and have been reported to act as both oncogenes and tumor suppressors. This study assessed...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-72
更新日期:2013-02-08 00:00:00